In the management of Rheumatoid Arthritis…
Look deeper into KEVZARA:
Revealing Clinical, Economic,
and Practical Value FOR YOUR PLAN
Look deeper into clinical value:
ILLUMINATING THE EVIDENCE
Targeted MOA that inhibits the effects
of chronically elevated IL-6
Observed Effects
of Sarilumab based on
PHARMACODYNAMIC studies1
A ROBUST CLINICAL PROGRAM SPANNING MTX-IR
and TNF-IR POPULATIONS
Adult patients with moderately to severely active RA, diagnosed based on ACR criteria
MTX-IR and TNF-IR
PATIENT POPULATIONS
Two Pivotal, Randomized,
Double-Blind, Placebo-
controlled Studies
HEAD-TO-HEAD
SUPERIORITY STUDY AS A
MONOTHERAPY
VS ADALIMUMAB
Two Pivotal, Randomized,
Monotherapy Study
(not included in KEVZARA USPI)
Long-term SAFETY AND EFFICACY data
Open-label extension (OLE) study limitations and additional study context
This was a comprehensive safety analysis from pooled studies of patients who received at least 1 dose of sarilumab in combination with DMARD(s) as of last data analysis on January 15, 2018.4
Efficacy assessments in this analysis did not include all of the primary endpoints from the placebo-controlled period of the pivotal trials analyzed.
For analysis of no radiographic progression, linear extrapolation was used to impute missing data. Patients with missing data after the imputation were considered progressors.4
Given the limitations and context described above, caution should be used in interpreting these data. Look Deeper
Look deeper into economic value:
Exposing the bottom line
COMPETITIVELY PRICED amongst RA products
A History of Significant Price Increases over the last 6 years
WAC PRICE INCREASES FOR SELF-ADMINISTERED RA THERAPIES5*
REDUCTIONS IN CRP LEVELS at Consistent q2W Dosing
Predictable budget impact
IN A CLAIMS ANALYSIS OF PATIENTS PRESCRIBED SC ACTEMRA CONSISTING OF DATA
FROM TRUVEN MARKETSCAN AND OPTUM CLINFORMATICS DATABASES…6*
62%EITHER INITIATED
OR ESCALATED
TO THE HIGHER
WEEKLY DOSE
37%
ESCALATED
FROM Q2W
TO QW
DOSING
These dose
escalations can
almost double
projected
annual cost
KEVZARA is the only IL-6
inhibitor that does not
require dose escalation1,7
STUDIED IN COST-EFFECTIVENESS ANALYSIS VS MARKET LEADER
Look deeper into practical value:
SURPASSING THE EXPECTED
For more information, call KevzaraConnect at 1-844-KEVZARA (1-844-538-9272) Option 1,
Monday–Friday, 8 AM–9 PM Eastern time.
look deeper
into value
CLICK HERE TO CONTACT
YOUR SANOFI
GENZYME
ACCOUNT DIRECTOR
FOR MORE
INFORMATION.
YOU’LL BE GLAD YOU DID.
References: